1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
NIH Brain Development Cohorts (NBDC) and Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access (X01 Clinical Trial Not Allowed) is sponsored by National Institute of Neurological Disorders and Stroke (NINDS). This funding opportunity provides the scientific community with access to biospecimens from the Adolescent Brain Cognitive DevelopmentSM (ABCD) Study, the HEALthy Brain and Child Development (HBCD) Study, and the Population Assessment of Tobacco and Health (PATH) Study.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
### Categories of Funding Other Native Tribal Organizations, Tribally Designated Housing Entities, Tribally-Owned Business Department of Health and Human Services National Institutes of Health ### Cost Sharing or Matching The National Institutes of Health seek to advance their mission by providing the scientific community with the opportunity to request access to biospecimens from the Adolescent Brain Cognitive DevelopmentSM (ABCD) Study, the HEALthy Brain and Child Development (HBCD) Study, and the Population Assessment of Tobacco and Health (PATH) Study to conduct research consistent with the respective study objectives that will maximize the scientific utility of these limited samples.
Applications should expand the knowledge gained from these studies and advance our understanding of the multiple genetic and environmental factors, such as exposure to substances, that affect health and disease over the course of a lifetime. ### Additional Information on Eligibility Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.
Foreign Organizations/Foreign CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
NIH will no longer issue awards (i.e., new, renewal, or non-competing continuation) to domestic or foreign entities that involve foreign subawards/subcontracts. All NIH-funded research involving foreign subawards/subcontracts must be submitted in response to a NOFO that is specifically designated for funded international collaborations. See NIH Grants Policy Statement 16.
8 Collaborative International Research Awards. Applications involving foreign subawards/subcontracts submitted in response to this NOFO will be deemed noncompliant and will not be considered for funding.
This policy applies to all monetary international collaborations resulting in foreign subawards/subcontracts, however, it does not preclude unfunded international collaborations or foreign components, funding for foreign consultants, or procurement of unique equipment or supplies from foreign vendors. ### Categories of Funding Activity
According to the current listing, eligibility includes: The scientific community, including universities, can request access to biospecimens to conduct research consistent with the study objectives. Confirm the full requirements in the official notice before applying.
Applications for NIH Brain Development Cohorts (NBDC) and Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access (X01 Clinical Trial Not Allowed) are due April 18, 2029. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
NIH Brain Development Cohorts (NBDC) and Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access (X01 Clinical Trial Not Allowed) is funded by National Institute of Neurological Disorders and Stroke (NINDS). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The AIR program is ARPA-H's most ambitious bet yet: fully autonomous robots that perform stroke-saving thrombectomies without a human surgeon. Proposals are due March 18. A strategic guide for applicants.
Read articlePAR-27-062 creates a three-year, $80,000-salary postdoctoral career award across NCI, NIAID, NIBIB, NIDCR and NINDS — and it carries a hard eligibility window that closes two years after you start your postdoc. Full analysis of the Academic Career Excellence Award, what it replaces, and why the timing rule is the whole competition.
Read articleThe HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read article